• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Compulsory Licensing of Pharmaceutical Patents System from the Perspective of Public Interest-Public Health in China

    2020-07-09 08:49:12ZhangYuboYuanHongmei
    亞洲社會(huì)藥學(xué)雜志 2020年1期

    Zhang Yubo,Yuan Hongmei

    (School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China)

    Abstract Objective To study the types and acquisition paths of drug data in the administrative act of compulsory licensing of pharmaceutical patents so as to provide data support for the implementation of compulsory licensing of pharmaceutical patents from the perspective of public interest-public health in China.Methods Situation of compulsory licensing of pharmaceutical patents in the context of public interest-public health in China was selected,combined with international conventions and the principle provisions of relevant laws,and cases of compulsory licensing of pharmaceutical patents in foreign countries were reviewed to extract drug-related data of compulsory licensing of pharmaceutical patents.Results and Conclusion According to the analysis of China’s compulsory licensing of pharmaceutical patents theory and legal provisions,the data could be divided into five categories for compulsory licensing of pharmaceutical patents in China:diseases,drugs,patents,generic drug enterprises,and licensing fees.Although,some data are traceable.There were also problems in obtaining data or inconsistent standards in five levels of compulsory licensing of pharmaceutical patents in the context of public interest-public health.It was not conducive to the implementation of compulsory licensing of pharmaceutical patents in China.Thus,it should be further established a unified data support system at the national level,specifying the standard of licensing fee,implementing relevant laws and regulations.

    Keywords:compulsory license; public interest; public health; data acquisition

    The compulsory licensing of pharmaceutical patents system has been recognized by the international community due to its incorporation into TRIPS.Some countries,such as the United States,India,and Thailand have used this system in practice and obtained good social benefits.This system is not strange in China,but there is no precedent of using this system in practice.Nowadays,the conditions for implementing the compulsory licensing of pharmaceutical patents system are mature.However,the implementation of this system involves many important and sensitive issues,such as the complex drug data types with specialty.Thus,in order to ensure the legality,science and order,accurate research and demonstration on the types of drugs involving data and acquisition paths become one of the necessary procedures to launch the preliminary preparation of compulsory licensing of pharmaceutical patents in China.Based on the research of theory and system,some drug data types and access path were studied to provide support for realizing the drug patent compulsory license under the condition of public interest-public health.Thus it can promote the implementation of the compulsory license,drug accessibility,and improve the protection of public health in China.

    1 The public interest-public health and compulsory licensing of pharmaceutical patents

    As an important part of the intellectual property system,TRIPS agreement stipulates the principles for the compulsory licensing of pharmaceutical patents[1],giving each country the right of free decision-making and it can design a compulsory licensing system of pharmaceutical patents according to its own national conditions.In practice,many countries explore the system design suitable for their own national conditions,and have achieved significant results.In view of the different situations of compulsory licensing of pharmaceutical patent and the particularity of each situation,it is believed that selecting a specific situation for research based on China’s national conditions is necessary.After repeated deliberation,we choose public interest-public health as the research entry point,and the reasons are the followings.

    First of all,the essential attribute of compulsory licensing strictly limits the start-up situation.Compulsory licensing is to deprive citizens’ legal private rights through administrative power.Thus,both TRIPS agreement and the laws of all countries in the world have made extremely strict regulations on the starting situation of this administrative act[2].They require that the different situation should be dealt with respectively.Therefore,a more broad and independent research horizon — the public interest-public health is selected as the research situation.

    The second is the international convention system design requirements.In 2001,all the member countries signed the Declaration on TRIPS and Public Health in Doha[3],which recognized that public health problems seriously affected many developing and the poorest countries,especially those suffering from AIDS,tuberculosis,malaria and other infectious diseases.In 2005,the WTO General Council adopted the Revised TRIPS Protocol,which elevated the contents made in Doha Health Declaration into a formal provision of TRIPS agreement in the form of a treaty,marking that public health,an integral part of public interest,became the legal basis for members to issue compulsory licensing of pharmaceutical patent.

    Then,the specific background of compulsory licensing in China was taken into consideration.According to China’s patent law,China’s patents compulsory licensing was divided into six situations,as shown in Table 1.

    Table 1 China’s patent law on patent licensing situations

    Firstly,the domestic patent compulsory licensing of the basic issues of theory and application should be clarified.Then,export dimensions should be clarified too.Based on the above considerations,this article selected (3) as the research situation.Due to the rare national emergency,the public interests are taken as the research key.In view of the fact that public interests in the world are within the scope of public health category of compulsory licensing of pharmaceutical patents,this paper focuses on public health in order to be more targeted and operable.Therefore,the chosen situation is public interest-public health.

    2 Elements of compulsory licensing of pharmaceutical patents from the perspective of Public interest-public health

    2.1 Drug factors

    Base on the trade-related intellectual property agreement amendment protocol,drug is defined as a patented product of pharmaceutical industry or a product produced by a patented process for public health.The active ingredients of the products and the diagnostic kits are also included[4].

    According to the Drug Administration Law of the People’s Republic of China in 2019,drugs refer to substances used for the prevention,treatment and diagnosis of human diseases,for the purpose of regulating human physiological functions and for prescribing indications,functions,usages and dosage,including traditional Chinese medicine,chemical drugs and biological products.Meanwhile,the detailed rules for the implementation of the patent law in article 73 pointed out that the patent drugs refers to any patented products used for public health or direct access to products in accordance with the patent method,including the patent right of manufacture for active ingredients of the products and diagnostic products.

    It can be found from the cases of compulsory licensing of pharmaceutical patents in India,Brazil,Thailand and other developing countries that the selection of target drugs for compulsory licensing should meet the following conditions,shown in Table 2.

    Table 2 Conditions of compulsory licensing of pharmaceutical patents in various countries

    According to the existing practice examples of compulsory licensing in foreign countries,it is believed that the patented drugs suitable for compulsory licensing should meet the following conditions.First,the substitutability of patented drugs is low.When the public are faced with health problems,the irreplaceable and important role of patented drugs is the first requirement for compulsory license of the target drugs.Second,the accessibility of the patented drug is poor.When the public are faced with health problems,they have a greater demand for patented drugs,so patented drugs must have adequate access.Third,the affordability of the patented drug is low.If the price of patented drugs is far beyond the public’s expectation,many patients will not receive good treatment,which seriously threatens the national health and quality of life.

    2.2 Patent elements

    In the term of patent protection,the following stipulations were made in article 28 of the TRIPS agreement.A patentee should have the following exclusive rights.For the product patent,the patentee has the right to prohibit the third party from engaging in these acts:manufacturing,using,and providing for the sale,selling,or importing the product for the above purposes without his consent.For the method patent,the patentee has the right to prohibit third parties from using the method without his consent as well as selling or importing products directly obtained by the method.The patentee shall have the right to assign or transfer patent through inheritance,and to conclude a license contract.

    Invention means creation,utility model and designs according to the patent law of China.It refers to a new technical proposal for a product,a method or an improvement.The method invention includes a technical proposal for an operation method,a manufacturing method and a technological process,etc.The term utility model refers to a new technical scheme for the shape,construction or combination of a product that is fit for use.Meanwhile,appearance design refers to the new design made on the shape,pattern or their combination.Besides,it is the combination of color,shape and pattern,which is rich in aesthetic feeling and suitable for industrial application.Therefore,it is believed that the patent of a drug suitable for compulsory licensing should have such condition that the patent related to the drug must be authorized in China and it is in an effective state.

    2.3 Definition of generic drug enterprise qualification

    The appendix of the revised protocol to the TRIPS agreement stipulated the criteria and methods for assessing the lack of productive capacity of importing countries[5].The production capacity of the pharmaceutical industry is as follows.

    The least developed member states are considered to have no or insufficient manufacturing capacity in the pharmaceutical industry.For other member states that are eligible for import,it can be determined by one of the following ways that they do not have or lack the production capacity for the relevant drugs.The member state has proved that it has no production capacity in the pharmaceutical industry,but it has some production capacity in the industry.The member state has been investigated that capacity is currently insufficient to meet its own needs except for the production capacity owned or controlled by the patent owner.The system may no longer apply to this member state when it is proved that the productive capacity is sufficient to meet its needs[6].

    Article 48 of the Patent Law in China provides that under any of the following circumstances,the patent administration department under the State Council may grant a compulsory licensing to exploit the patent for invention or utility model upon the application of any qualified entity or individual.The above having the conditions for implementation indicates the qualifications of generic drug enterprises in compulsory licensing of pharmaceutical patents.Firstly,it should have the technical conditions to manufacture patented products with patented methods.Secondly,it has the capital and assets conditions.Thirdly,it should meet the market supervision requirements for manufacturing patented products with patented methods,and have the market access qualification.If the exploitation of the patent by the licensee under compulsory licensing belongs to the licensee’s import of the patented product,the conditions for implementation mentioned in article 48 should be interpreted as follows.First,the import and export of the patented technology and product should comply with the requirements of the import and export control regulations of the relevant country.Second,it must have proof of funds.

    2.4 Definition of license fee

    In 2012,Indian Patent Office issued a compulsory license for the anti-cancer drug Nexamei,and Indian generic drug company Natco had to pay Bayer a patent fee of 6% of sales[7].The Thai government issued a compulsory license for Efavirenz.The government recommended a license fee of 0.5% of the generic drug price.The amount of the generic drug price was determined by the additional negotiation between the licensee and the patentee.In 2003,in order to import the generic drug of the patented drug ARV from the Indian company CIPLA,Malaysia issued a compulsory license for the import of Zidovudine,Didanosine and Zidoramide Difudine from India by the Ministry of Domestic Trade and Consumer Affairs within 2 years.As to compensation,the Ministry of Health proposed to give the patentee 4% of the actual shipment value per year,but the patent holder did not accept this compensation[8].By summarizing the calculation of the compulsory license fee in various countries,four modes were sorted out[9-10].They are UNDP mode,Canadian mode,fixed ratio method,and tort compensation method.

    2.4.1 UNDP model

    The UNDP Human Development Report recommends a simple system of patent royalty guidelines,which is primarily for developing countries with the aim of ensuring the transparency and predictability of compulsory licenses.The basic compensation is 4% of the generic drug price,which can be increased or decreased by 2% depending on the degree of innovation of the drug or the government’s investment in research and development.Therefore,the compensation fee is 2% to 6% of the generic drug price.

    2.4.2 Canadian model

    The Canadian government has developed a guideline on royalty for compulsory licensing of pharmaceutical patents imported by countries that lack pharmaceutical capabilities.According to the national ranking in the UNDP Human Development Index (HDI),the compensation ratio is 0.02% to 4%.For most developing countries,the ratio is less than 3%,and for most African countries,the ratio is less than 1% (Compulsory license fee ratio=0.04 * (178 -Drug importing country HID ranking)/ 177).

    2.4.3 Fixed ratio method

    It refers to the determination of the compensation fee for compulsory license according to a certain proportion of the sales of patented products.There are two ways.One is to determine the proportion of patent royalties by the discretionary authority to exercise discretion in specific cases.The other is to determine the proportion of royalties through legislation or lawsuit.

    2.4.4 Tort compensation method

    It is originated from the Diddell v.Vickers case in the United Kingdom.According to this method,the compensation for patent compulsory licenses should be calculated based on the amount of compensation that should be paid for infringement of patent rights.

    At present,Patent Law of China,Patent Law Implementation Rules and Patent Implementation Compulsory License Measures have not clearly explained the reasonable use fee.Besides,there is no compulsory license fee measurement example.So when the license is used to carry out the enforcement in the future,the measurement of the license fee can be drawn from the above four models in foreign countries.In the case of simulation,this paper also studied the data points involved in the four calculation methods of license fee to provide reference for the future compulsory license in China.

    3 Public interest-public health compulsory license program data design

    The starting point of this study is compulsory licensing of pharmaceutical patents in the public interest-public health context.The types of data needed by compulsory licensing of pharmaceutical patents and the acquisition path in the public interestpublic health context are chosen according to the relevant legal provisions mentioned references.After the previous analysis of the legal provisions and examples of compulsory licenses,the data are finally classified into five categories,which include disease data,drug data,patent data,generic drug enterprise data and license fee data.

    3.1 Selecting disease data

    In terms of diseases,data on seven aspects are selected,including macroscopic statistics of diseases,chronic non-communicable diseases,sexually transmitted diseases,AIDS,viral diseases,tuberculosis,parasitic diseases and infectious diseases.Among them,the Yearbook of National Health and Family Planning Commission Statistical provided macroscopic statistics on 28 infectious diseases and deaths from the reports of Class A and B.The number of incidence,mortality and death of 28 infectious diseases are shown in each year or province.The 28 infectious diseases are classified into different age groups,genders,and statistics on the mortality of urban and rural areas.At the Center for Disease Control and Prevention of China,the status of chronic non-communicable diseases,sexually transmitted diseases and AIDS can be checked.In addition,monitoring dynamic information on viral diseases,tuberculosis and parasitic diseases can be provided as well.Last,the Emergency Command Center for Public Health can also provide an epidemic report when an infectious disease occurs.

    Thus,it is not difficult to observe disease conditions from various channels and comprehensive information to support the data acquisition and analysis of the compulsory licensing program.

    3.2 Selecting drug data

    In terms of drugs,the substitutability,accessibility,and affordability are the key factors to determine whether a patented drug could become a public interest-public health target.As to substitutability,it should include three levels of data such as technical information,safety information and market information.The Drug Evaluation Center of the State Drug Administration is responsible for conducting technical reviews of drug registration applications and providing technical information services.The National Adverse Drug Reaction Monitoring Center can get the reports about adverse drug reaction.The health administrative department can obtain the information of market occupancy through public hospitals.In addition,the information on the supply of medicines in public hospitals and retail pharmacies in key cities can also be obtained through the intranet and China Medical Industry Information Center.For accessibility,it can be considered from the four levels of domestic production capacity,production,import volume and reserves.Local Drug Regulatory Departments master production capacity information of pharmaceutical personnel and equipment.Meanwhile,the production information is reported by enterprises and the import quantity information is supervised by the Port Drug Supervision Bureau which allows the import.The State Material Reserve Bureau,a subordinate unit of the National Development and Reform Commission,prepares a catalogue of national strategic material reserves,and supervises the quantity,quality and storage safety of the reserve strategic materials so that it can grasp the information on the amount of relevant medicines.In terms of affordability,it can be considered from the three levels of sales price,patient payment ability,and medical insurance reimbursement.The drug sales price data mainly includes the drug bidding price of the health administrative department and the recruitment platform.Patients’ capability of paying mainly includes the total health expenditure per capita,health care expenditure per capita and proportion in all provinces provided by the Health and Health Commission,as well as GDP per capita,income per capita and consumption expenditure provided by the National Bureau of Statistics.The medical insurance reimbursement data mainly includes the medical insurance reimbursement information of the National Basic Medical Insurance,the Work Injury Insurance and Maternity Insurance Drug List provided by the Ministry of Human Resources and Social Security,and the annual medical insurance expenditure per capita.In addition,personal payment ratio data of the B medicines are provided by the municipal social security bureau.

    Through the above analysis,it is not difficult to find that the situation of drugs can be observed from a variety of channels and information to provide support for data acquisition and analysis of compulsory licensing procedures.

    3.3 Selecting patent data

    In the aspect of patents,we need to know the information of drugs,the basic information of patents,the technical information of patents,and the legal status of patents.

    Pharmaceutical patent information can be obtained from the publication of patents related to drug registration of the State Drug Administration and the collection of listed drug catalogues in China.Information on the basic technology and legal status of patents can be obtained from the patent retrieval module of the website of the State Intellectual Property Office of China and IncoPat Patent Database.Information on patent challenges can be retrieved from the intellectual property module of the Judgment Document of China’s Supreme People’s Court’s.

    Through the above analysis,it is not difficult to find that patents can be observed from a variety of channels and information to provide support for data acquisition and analysis of compulsory licensing procedures.

    3.4 Data selection of generic pharmaceutical enterprises

    As to generic pharmaceutical enterprises,their qualification,copying ability,and cost accounting of generic drugs are essential elements for them to be the candidates for compulsory license of pharmaceutical patents.Qualifications of generic pharmaceutical enterprises and their business license information can be obtained from the State Administration of Market Supervision-State Enterprise Credit Information Publicity System.But the conclusion document of on-the-spot inspection of copying ability and the production compatible with the production of drugs can be consulted with the local drug regulatory authorities,or through the Shenzhen Stock Exchange and Shanghai Securities Exchange.Information acquired by exchanges can be used to measure the imitation ability of enterprises,and the information of enterprises applying for production registration can also be known in the information disclosure module of the drug evaluation center.

    In addition,the administrative matters acceptance service module can inquire about the progress of drug registration according to the drug acceptance number.As for the cost accounting of generic drugs,it is often necessary to check the progress of drug registration according to the drug acceptance number.It takes selfreport to get it.Through the above analysis,it is easy to find that the situation of generic pharmaceutical enterprises can be observed from a variety of channels and information for data acquisition and analysis of compulsory licensing procedures.

    3.5 Selecting data of license fee

    In terms of licensing fee,because there is no precedent in China,we can only learn from some models abroad,mainly the above four models:UNDP model,Canadian model,fixed proportion law,tort damage compensation law.The formula of UNDP model means Licensing fee=Generic drug price * (2%-6%).The formula of Canadian model is Licensing fee=Generic drug price * Licensing fee ratio.Licensing fee ratio=0.04 * (178 -HID ranking of drug importing countries)/ 177.Its formula of fixed proportion method is Licensing fee=Sales volume * A certain proportion (case specific analysis,recommended 4%-6%).Tort compensation method includes the following ways,such as calculating licensing fee based on the actual loss of the patent holder,Licensing fee=Reasonable profit of the unit patented product * Sales volume of the infringed product.The second is based on the profits obtained from the infringement,Licensing fee=Operating profit of the unit infringed product * Sales volume of infringed products.The third is calculated by the people’s court with fixed compensation,Licensing fee=More than 10 000 yuan,less than 1 million yuan.The calculation is based on the cost recovery of original research and development of drugs.The specific data acquisition methods of each formula have been described before.The formula can be obtained from various channels and information to calculate the required data.Therefore,the licensing fees of different models can be calculated to support the data acquisition and analysis of compulsory licensing procedures.

    4 Conclusions and suggestions

    The design of the international drug patent compulsory licensing system is analyzed and combined with our own national conditions.And then the situation of public interest-public health compulsory licensing is chosen as the starting point.According to the international conventions and the relevant laws and regulations of China,the connotation of public interest-public health in the context of our country was discussed,and the cases of compulsory licensing of pharmaceutical patents in India,Brazil and Thailand were analyzed to design the implementation of compulsory licensing of pharmaceutical patents.Data acquisition path can provide data support to promote the follow-up implementation of compulsory license of pharmaceutical patents in China.But it can be seen from the article that although some data are traceable,there are still some data without uniform provisions.So some suggestions are put forward.

    4.1 Establishing a unified data support system

    It can be seen from the fourth part of this article that drug data of patent compulsory licensing is complex,involving the official data of National health commission,food and drug administration,the state intellectual property office,the national bureau of statistics,ministry of industry,the national development and reform commission,the general administration of customs as well as other administrative agencies.It also involve in other technical data such as epidemic,pharmaceutical production consistency,generic drugs registration and drug patents,medical insurance as well as market prices and raw material supply.Corresponding data support system should be established by the government to improve the feasibility of compulsory licensing of pharmaceutical patents.

    4.2 Specifying the license fee standard

    The reasonable royalty in the patent law needs clear and operable standards.TRIPS agreement stipulates that adequate compensation should be given on the premise of the economic value factors of the authorization,but it does not define the method or standard.This article has mentioned that India,Thailand,Canada and Malaysia have their own compulsory licensing fees for drugs.The above information can be used as the preparation for China to determine the compulsory licensing fees for drugs.

    4.3 Realizing the systematic and scientific compulsory license law

    The fourth revision of the patent law can be taken as an opportunity to integrate and improve the regulatory system of compulsory licensing of pharmaceutical patents.In setting up the legal standard system,provisions of the legislation law on the scope of legislative power should be strictly followed,and the types,causes,conditions and main procedures of the compulsory licensing of pharmaceutical patents system must be further clarified.According to the needs,the administrative regulations of compulsory license or compulsory licensing of pharmaceutical patents should be formulated to refine procedural and operational regulations[3].A regulatory system of compulsory licensing of pharmaceutical patents should be formed,which is clear in legal effect,concise in expression,and easy to operate.

    亚洲人成电影观看| 色老头精品视频在线观看| 丝袜喷水一区| 亚洲精品成人av观看孕妇| 成年人午夜在线观看视频| 国产亚洲精品一区二区www | 精品第一国产精品| www.熟女人妻精品国产| 人人妻人人澡人人看| 欧美精品一区二区大全| 美女高潮到喷水免费观看| 亚洲第一青青草原| 亚洲国产看品久久| 久久久欧美国产精品| 高清视频免费观看一区二区| 久久性视频一级片| e午夜精品久久久久久久| 国精品久久久久久国模美| 亚洲欧美日韩另类电影网站| 国产精品香港三级国产av潘金莲| 狠狠狠狠99中文字幕| 别揉我奶头~嗯~啊~动态视频| 久久ye,这里只有精品| 一边摸一边抽搐一进一出视频| 97在线人人人人妻| 国产有黄有色有爽视频| 老汉色∧v一级毛片| 波多野结衣av一区二区av| 露出奶头的视频| 又大又爽又粗| 久久影院123| 黄色视频在线播放观看不卡| 欧美黑人精品巨大| 高清毛片免费观看视频网站 | 国内毛片毛片毛片毛片毛片| 18禁美女被吸乳视频| 极品人妻少妇av视频| 啦啦啦中文免费视频观看日本| 国产无遮挡羞羞视频在线观看| 国产精品国产av在线观看| 久久免费观看电影| 久久午夜综合久久蜜桃| 国产亚洲一区二区精品| 黄片小视频在线播放| 国产黄色免费在线视频| 人人澡人人妻人| 久热爱精品视频在线9| 久久狼人影院| 久久精品成人免费网站| 黄色a级毛片大全视频| 成人特级黄色片久久久久久久 | 夜夜夜夜夜久久久久| 王馨瑶露胸无遮挡在线观看| 欧美av亚洲av综合av国产av| 69av精品久久久久久 | 欧美黑人欧美精品刺激| 超色免费av| 一级毛片电影观看| 蜜桃国产av成人99| 一二三四社区在线视频社区8| 黄片大片在线免费观看| 黄色a级毛片大全视频| 欧美日韩黄片免| 一本一本久久a久久精品综合妖精| 1024视频免费在线观看| 国产精品一区二区免费欧美| 亚洲精品国产区一区二| 成年人免费黄色播放视频| 欧美人与性动交α欧美精品济南到| 青青草视频在线视频观看| 另类精品久久| 久久av网站| 久久性视频一级片| 91精品国产国语对白视频| 少妇粗大呻吟视频| 一个人免费在线观看的高清视频| 黄色片一级片一级黄色片| 亚洲色图综合在线观看| 国产男靠女视频免费网站| 午夜福利在线免费观看网站| 久久久国产一区二区| 五月天丁香电影| 男女无遮挡免费网站观看| 久久久久久久精品吃奶| 高清在线国产一区| 999久久久精品免费观看国产| 欧美黄色片欧美黄色片| 操出白浆在线播放| 亚洲av片天天在线观看| 亚洲精品在线观看二区| 最近最新中文字幕大全免费视频| 精品久久蜜臀av无| 国产精品免费视频内射| 久久久水蜜桃国产精品网| 欧美人与性动交α欧美精品济南到| 99精品在免费线老司机午夜| av天堂在线播放| 天天添夜夜摸| 亚洲avbb在线观看| 999精品在线视频| 国产在线免费精品| 国产97色在线日韩免费| 亚洲精品一卡2卡三卡4卡5卡| 80岁老熟妇乱子伦牲交| 操出白浆在线播放| 欧美精品啪啪一区二区三区| 欧美午夜高清在线| 精品熟女少妇八av免费久了| 热re99久久国产66热| 99国产极品粉嫩在线观看| 国产精品av久久久久免费| 国产97色在线日韩免费| 国产精品亚洲一级av第二区| 亚洲中文av在线| 国产麻豆69| 91九色精品人成在线观看| 人人妻,人人澡人人爽秒播| 丝袜美腿诱惑在线| 色尼玛亚洲综合影院| 搡老熟女国产l中国老女人| 欧美 亚洲 国产 日韩一| 国产高清国产精品国产三级| 亚洲专区字幕在线| 99久久人妻综合| 视频区欧美日本亚洲| 男人操女人黄网站| 9色porny在线观看| 午夜激情av网站| 亚洲欧美色中文字幕在线| 欧美日韩中文字幕国产精品一区二区三区 | 亚洲专区中文字幕在线| 中文字幕人妻丝袜一区二区| a级毛片在线看网站| 日韩中文字幕视频在线看片| 真人做人爱边吃奶动态| 国产精品98久久久久久宅男小说| 午夜视频精品福利| 久久久欧美国产精品| 国产精品久久久久久人妻精品电影 | 日韩大片免费观看网站| 午夜成年电影在线免费观看| 国产高清国产精品国产三级| 日日摸夜夜添夜夜添小说| 妹子高潮喷水视频| 午夜福利欧美成人| 国产午夜精品久久久久久| 久久精品91无色码中文字幕| 日本wwww免费看| 最近最新中文字幕大全电影3 | 国产97色在线日韩免费| 精品久久久精品久久久| 午夜福利一区二区在线看| 中文欧美无线码| 国精品久久久久久国模美| 日本五十路高清| 亚洲一码二码三码区别大吗| 怎么达到女性高潮| 欧美av亚洲av综合av国产av| 久久精品亚洲av国产电影网| 国产精品久久久久成人av| 一区福利在线观看| 两性夫妻黄色片| 丁香六月欧美| 久久亚洲精品不卡| 香蕉国产在线看| 国产1区2区3区精品| 国产男靠女视频免费网站| 大型av网站在线播放| 伦理电影免费视频| 女人高潮潮喷娇喘18禁视频| 欧美日韩成人在线一区二区| 精品久久久精品久久久| 亚洲av美国av| 久久精品国产99精品国产亚洲性色 | 午夜福利欧美成人| av福利片在线| 亚洲专区国产一区二区| 精品久久久久久久毛片微露脸| 日韩中文字幕视频在线看片| 动漫黄色视频在线观看| 久久中文字幕人妻熟女| 50天的宝宝边吃奶边哭怎么回事| 啦啦啦免费观看视频1| 超色免费av| 大片免费播放器 马上看| 精品国产一区二区三区四区第35| 女警被强在线播放| 一级黄色大片毛片| 91av网站免费观看| 久久青草综合色| 丁香欧美五月| 欧美日韩成人在线一区二区| 热99国产精品久久久久久7| 亚洲,欧美精品.| 亚洲国产av新网站| 热re99久久精品国产66热6| 极品教师在线免费播放| 精品一区二区三区av网在线观看 | 亚洲熟女精品中文字幕| 曰老女人黄片| 国产成人精品在线电影| svipshipincom国产片| 日韩免费av在线播放| 亚洲精品中文字幕一二三四区 | 国内毛片毛片毛片毛片毛片| 国产高清videossex| 午夜精品国产一区二区电影| 国产精品久久久久久人妻精品电影 | 在线观看免费视频网站a站| 久久午夜亚洲精品久久| 精品福利观看| 女性生殖器流出的白浆| 国产日韩一区二区三区精品不卡| 99re在线观看精品视频| 波多野结衣一区麻豆| 中文字幕精品免费在线观看视频| 国产欧美亚洲国产| 亚洲精品国产色婷婷电影| 老熟女久久久| 制服诱惑二区| 精品福利观看| 中文字幕另类日韩欧美亚洲嫩草| 免费一级毛片在线播放高清视频 | 人人妻人人添人人爽欧美一区卜| h视频一区二区三区| 别揉我奶头~嗯~啊~动态视频| 女性被躁到高潮视频| 十八禁网站网址无遮挡| 国产高清videossex| 十八禁高潮呻吟视频| 色精品久久人妻99蜜桃| 日韩免费高清中文字幕av| 国产不卡av网站在线观看| 精品久久久久久电影网| 蜜桃国产av成人99| 久久久久国内视频| 中文字幕精品免费在线观看视频| 成人免费观看视频高清| 欧美精品av麻豆av| 啦啦啦免费观看视频1| 99香蕉大伊视频| 激情在线观看视频在线高清 | 18禁黄网站禁片午夜丰满| 国产精品一区二区精品视频观看| 国内毛片毛片毛片毛片毛片| 日日夜夜操网爽| 80岁老熟妇乱子伦牲交| 亚洲国产欧美在线一区| 午夜免费成人在线视频| 久久香蕉激情| 精品国产亚洲在线| 一级片免费观看大全| netflix在线观看网站| 久久中文看片网| 极品人妻少妇av视频| 国产亚洲一区二区精品| 亚洲国产精品一区二区三区在线| 精品久久久精品久久久| 视频区欧美日本亚洲| 久久影院123| 国产日韩欧美在线精品| 亚洲伊人久久精品综合| 国产亚洲一区二区精品| 1024视频免费在线观看| 精品福利观看| 免费女性裸体啪啪无遮挡网站| 怎么达到女性高潮| 日韩欧美三级三区| 国产高清videossex| 色在线成人网| 性少妇av在线| 丝袜在线中文字幕| 91国产中文字幕| 色老头精品视频在线观看| 亚洲av电影在线进入| 制服人妻中文乱码| 丝袜喷水一区| 中文字幕人妻熟女乱码| 久久久精品区二区三区| 亚洲一区二区三区欧美精品| 天天躁日日躁夜夜躁夜夜| 人人妻人人爽人人添夜夜欢视频| 免费av中文字幕在线| 男女午夜视频在线观看| 视频区图区小说| 中文亚洲av片在线观看爽 | 老司机福利观看| 成人国产一区最新在线观看| 亚洲一卡2卡3卡4卡5卡精品中文| 建设人人有责人人尽责人人享有的| 黄频高清免费视频| 精品卡一卡二卡四卡免费| 国产伦理片在线播放av一区| svipshipincom国产片| 午夜福利视频在线观看免费| 操出白浆在线播放| 免费在线观看影片大全网站| 中文欧美无线码| 亚洲午夜理论影院| 老汉色av国产亚洲站长工具| 精品少妇久久久久久888优播| 80岁老熟妇乱子伦牲交| 日韩中文字幕视频在线看片| 波多野结衣av一区二区av| 免费在线观看黄色视频的| 黑人巨大精品欧美一区二区mp4| 中文字幕人妻丝袜制服| 精品国产国语对白av| 捣出白浆h1v1| 午夜免费鲁丝| 日本精品一区二区三区蜜桃| 久久国产精品人妻蜜桃| 他把我摸到了高潮在线观看 | 亚洲,欧美精品.| 美女扒开内裤让男人捅视频| 999精品在线视频| 亚洲精华国产精华精| 日韩免费高清中文字幕av| 国产精品.久久久| 91老司机精品| 人人妻人人爽人人添夜夜欢视频| svipshipincom国产片| 欧美在线黄色| 中文字幕色久视频| 国产亚洲精品第一综合不卡| 成人国产av品久久久| 波多野结衣一区麻豆| 国产视频一区二区在线看| 亚洲av欧美aⅴ国产| 在线十欧美十亚洲十日本专区| 90打野战视频偷拍视频| 日日摸夜夜添夜夜添小说| 亚洲,欧美精品.| 成人18禁在线播放| 欧美黑人精品巨大| 免费av中文字幕在线| 美女午夜性视频免费| 国产区一区二久久| 十八禁高潮呻吟视频| 国产黄色免费在线视频| 天天躁日日躁夜夜躁夜夜| 99在线人妻在线中文字幕 | 国产精品一区二区免费欧美| 高清视频免费观看一区二区| 精品一区二区三区av网在线观看 | 欧美另类亚洲清纯唯美| 亚洲精品久久成人aⅴ小说| 婷婷丁香在线五月| 国产又色又爽无遮挡免费看| 欧美另类亚洲清纯唯美| 日韩欧美一区视频在线观看| 丰满人妻熟妇乱又伦精品不卡| 久久狼人影院| 夫妻午夜视频| 国产免费av片在线观看野外av| 久久久国产一区二区| 亚洲第一av免费看| 熟女少妇亚洲综合色aaa.| 国产真人三级小视频在线观看| 可以免费在线观看a视频的电影网站| 涩涩av久久男人的天堂| 亚洲精品乱久久久久久| 免费少妇av软件| 少妇的丰满在线观看| 午夜福利视频在线观看免费| 777米奇影视久久| 色在线成人网| 自拍欧美九色日韩亚洲蝌蚪91| 亚洲国产毛片av蜜桃av| 亚洲第一欧美日韩一区二区三区 | 热99re8久久精品国产| 久久久久久久大尺度免费视频| 成人黄色视频免费在线看| 欧美亚洲日本最大视频资源| 日韩有码中文字幕| av线在线观看网站| 亚洲伊人久久精品综合| 久久精品国产a三级三级三级| 99久久国产精品久久久| 99久久人妻综合| 精品久久久久久电影网| 无遮挡黄片免费观看| 亚洲精品乱久久久久久| 国产淫语在线视频| 色尼玛亚洲综合影院| 国产精品久久久人人做人人爽| 欧美中文综合在线视频| 久久天堂一区二区三区四区| 黄片播放在线免费| 国产一区二区激情短视频| 丁香六月欧美| 国产av精品麻豆| 欧美乱码精品一区二区三区| 中文字幕人妻丝袜制服| 手机成人av网站| 夜夜爽天天搞| 国产视频一区二区在线看| 大香蕉久久成人网| 12—13女人毛片做爰片一| 99精品久久久久人妻精品| 亚洲国产欧美日韩在线播放| 国产成人一区二区三区免费视频网站| 好男人电影高清在线观看| 亚洲国产av影院在线观看| 日本五十路高清| 亚洲免费av在线视频| 涩涩av久久男人的天堂| 一本色道久久久久久精品综合| 搡老岳熟女国产| 老司机福利观看| 国产不卡一卡二| √禁漫天堂资源中文www| 久久精品国产亚洲av香蕉五月 | 中文亚洲av片在线观看爽 | 久久99热这里只频精品6学生| 老汉色av国产亚洲站长工具| 成人精品一区二区免费| 肉色欧美久久久久久久蜜桃| 手机成人av网站| 色精品久久人妻99蜜桃| 亚洲精品国产区一区二| 日本wwww免费看| 在线观看人妻少妇| 国产精品 欧美亚洲| 国产免费av片在线观看野外av| 91大片在线观看| 免费在线观看完整版高清| 免费在线观看日本一区| 大陆偷拍与自拍| 不卡av一区二区三区| cao死你这个sao货| 国产日韩欧美视频二区| 国产精品美女特级片免费视频播放器 | 黄片大片在线免费观看| 亚洲国产成人一精品久久久| 99热网站在线观看| 亚洲国产看品久久| 成人18禁高潮啪啪吃奶动态图| 99热国产这里只有精品6| 蜜桃国产av成人99| 色婷婷av一区二区三区视频| 日韩 欧美 亚洲 中文字幕| 国产片内射在线| 十八禁网站网址无遮挡| 精品久久久精品久久久| av超薄肉色丝袜交足视频| 在线观看www视频免费| 欧美日韩福利视频一区二区| 亚洲成人免费av在线播放| 亚洲综合色网址| 亚洲精品一二三| av国产精品久久久久影院| 久久精品人人爽人人爽视色| 女性被躁到高潮视频| 最新的欧美精品一区二区| 国产高清视频在线播放一区| 亚洲精品乱久久久久久| 1024香蕉在线观看| 中文字幕高清在线视频| 大型av网站在线播放| 黄网站色视频无遮挡免费观看| 别揉我奶头~嗯~啊~动态视频| 国产在线一区二区三区精| av又黄又爽大尺度在线免费看| 久久毛片免费看一区二区三区| 免费在线观看日本一区| 中文字幕人妻丝袜制服| 中文亚洲av片在线观看爽 | 精品卡一卡二卡四卡免费| 亚洲av日韩在线播放| 侵犯人妻中文字幕一二三四区| 久久香蕉激情| 国产日韩欧美在线精品| 久久久久久久久免费视频了| 免费高清在线观看日韩| 亚洲精品一卡2卡三卡4卡5卡| 后天国语完整版免费观看| 日韩欧美国产一区二区入口| 欧美成人免费av一区二区三区 | 久久午夜综合久久蜜桃| 久久久国产精品麻豆| 女性被躁到高潮视频| 91国产中文字幕| 亚洲伊人色综图| 欧美中文综合在线视频| 亚洲精品粉嫩美女一区| 欧美性长视频在线观看| 国产色视频综合| 十八禁高潮呻吟视频| 2018国产大陆天天弄谢| 亚洲成av片中文字幕在线观看| 美女福利国产在线| 日本a在线网址| 一区二区三区激情视频| 欧美日韩视频精品一区| 国产高清视频在线播放一区| 叶爱在线成人免费视频播放| 精品国内亚洲2022精品成人 | 亚洲国产看品久久| 国产成人啪精品午夜网站| av天堂在线播放| 亚洲成a人片在线一区二区| 国产亚洲精品第一综合不卡| 可以免费在线观看a视频的电影网站| 国产精品久久久人人做人人爽| 亚洲成a人片在线一区二区| 国产免费av片在线观看野外av| 菩萨蛮人人尽说江南好唐韦庄| 国产主播在线观看一区二区| 中文字幕色久视频| 欧美黑人欧美精品刺激| 制服人妻中文乱码| 久久中文字幕人妻熟女| 亚洲中文字幕日韩| 欧美成狂野欧美在线观看| 在线观看人妻少妇| 国产97色在线日韩免费| 欧美老熟妇乱子伦牲交| 午夜免费鲁丝| 一夜夜www| 久久精品亚洲熟妇少妇任你| 成年人黄色毛片网站| 每晚都被弄得嗷嗷叫到高潮| av网站在线播放免费| 久久精品aⅴ一区二区三区四区| 91老司机精品| 国产一区二区激情短视频| a级毛片黄视频| 天天操日日干夜夜撸| 婷婷成人精品国产| 国产成人欧美在线观看 | 国产男女超爽视频在线观看| 亚洲精品一卡2卡三卡4卡5卡| 99热国产这里只有精品6| 亚洲国产看品久久| 一级毛片精品| 欧美精品一区二区大全| 大型黄色视频在线免费观看| 亚洲第一欧美日韩一区二区三区 | 亚洲成人国产一区在线观看| 在线观看舔阴道视频| 99riav亚洲国产免费| 黄色 视频免费看| 午夜老司机福利片| 蜜桃在线观看..| 丰满迷人的少妇在线观看| 岛国毛片在线播放| 757午夜福利合集在线观看| 大陆偷拍与自拍| 国产日韩欧美视频二区| 最新在线观看一区二区三区| 丁香欧美五月| 日日爽夜夜爽网站| 国产欧美日韩一区二区三| 欧美乱码精品一区二区三区| 成人手机av| 不卡一级毛片| 午夜激情久久久久久久| 久久毛片免费看一区二区三区| 欧美日韩国产mv在线观看视频| 香蕉丝袜av| 999精品在线视频| 精品熟女少妇八av免费久了| 两个人免费观看高清视频| 亚洲午夜理论影院| 在线看a的网站| 日韩免费av在线播放| 精品一区二区三区四区五区乱码| 1024香蕉在线观看| 日日摸夜夜添夜夜添小说| 久久天躁狠狠躁夜夜2o2o| 精品一区二区三区视频在线观看免费 | 美女福利国产在线| 久久中文字幕一级| 亚洲精品一卡2卡三卡4卡5卡| 这个男人来自地球电影免费观看| 久久久久久人人人人人| 免费av中文字幕在线| av在线播放免费不卡| 最新美女视频免费是黄的| 人人妻人人爽人人添夜夜欢视频| 欧美精品啪啪一区二区三区| 中亚洲国语对白在线视频| 另类精品久久| 2018国产大陆天天弄谢| kizo精华| 不卡av一区二区三区| 久久久久久久久久久久大奶| 日韩制服丝袜自拍偷拍| 可以免费在线观看a视频的电影网站| 另类亚洲欧美激情| 高清欧美精品videossex| 男女边摸边吃奶| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲avbb在线观看| 国产免费现黄频在线看| 女性被躁到高潮视频| 成人手机av| 成年动漫av网址| 淫妇啪啪啪对白视频| 久久久久久久精品吃奶| 麻豆乱淫一区二区| 成人三级做爰电影| 免费高清在线观看日韩| 黄色视频在线播放观看不卡| 夜夜夜夜夜久久久久| 国产av一区二区精品久久| 一本大道久久a久久精品| 夜夜爽天天搞| 黑人巨大精品欧美一区二区蜜桃| 久久国产精品人妻蜜桃| 午夜福利在线免费观看网站| 国产精品久久久久久精品古装| 极品人妻少妇av视频| 捣出白浆h1v1|